Diflunisal Offlabel denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for diflunisal offlabel are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied This Off-Label Diflunisal Claim

Diflunisal is an FDA-approved NSAID, but when it is prescribed for an indication not listed in its approved labeling — most commonly for transthyretin amyloid cardiomyopathy (ATTR-CM) or related amyloid conditions — Humana will frequently issue a "not FDA-approved for this indication" denial. This is a coverage classification argument, not a clinical safety argument, and it is fully appealable.

## Why This Is Appealable

Federal and state coverage rules distinguish between FDA approval of a drug and the legitimate off-label use of that drug. Most commercial and Medicare Advantage plans — including Humana — are required under applicable law and accreditation standards to cover off-label uses that are supported by recognized compendia (such as Micromedex, DrugDex, or Clinical Pharmacology) or by substantial clinical evidence in peer-reviewed literature. The denial letter may cite "not an approved indication," but that framing does not end the inquiry.

## Federal Appeal Framework

• Internal appeal: You have 180 days from the denial notice to file. Humana must respond within 30 days for prospective requests and 60 days for post-service claims.
• External review (ACA §2719): If the internal appeal fails, you may request an independent external review within 4 months of the final internal denial. An accredited Independent Review Organization (IRO) — not Humana — makes the binding decision.
• ERISA §503 (self-funded plans): If your plan is employer-sponsored and self-funded, you have the right to a full-and-fair review, and federal courts can review procedural compliance.
• Expedited review: If the standard timeline would seriously jeopardize your health, request expedited review at every level.

## Documentation to Gather

1. Diagnosis confirmation — pathology, biopsy, or imaging results confirming the diagnosis your prescriber is treating. 2. Prescriber medical-necessity letter — a detailed letter explaining why diflunisal is clinically appropriate for your specific condition, referencing peer-reviewed literature and/or the applicable compendia citation. 3. Compendia support — a printout or citation from a recognized compendium listing diflunisal for your indication. 4. Treatment history — a chronological record of all treatments tried previously, with dates and documented outcomes. 5. Clinical severity documentation — chart notes, lab values, and functional assessments showing the severity of your condition.

## Criteria-Mapping Structure

Humana's off-label coverage policy lists specific compendia or evidence standards a drug must meet. Pull the exact current policy from Humana's medical policy portal, copy each requirement, and answer each with a specific chart fact or literature citation:

| Policy Requirement | Your Supporting Documentation | |---|---| | Recognized compendia citation or peer-reviewed evidence | [Prescriber to supply] | | Diagnosis confirmed by appropriate testing | [Attach relevant report] | | Clinical rationale for this agent over approved alternatives | [Prescriber letter] |

Always verify the exact criteria against Humana's currently published medical policy, not this summary — policies are updated and only the live policy controls your appeal.